Flu shot batch under review, Manitoba not reporting serious side effects

Share:

A flu shot that was sent to Manitoba health-care providers is being shelved pending a safety review, but experts say it shouldn’t deter you from getting a shot this year.

The Flulaval Tetra lot number KX9F7 is being investigated after three people in New Brunswick reported adverse effects.

Health officials say neurologic symptoms, which included sustained numbness or weakness of the face or limbs, occurred within seven days of receiving the vaccine.

This lot was received and shipped to Manitoba health-care providers between Oct. 22 and Nov. 11.

In a letter sent to health-care providers in Manitoba, the province asked them not to use the vaccine and to “check your vaccine supply for FluLaval Tetra vaccine with lot number KX9F7 and mark ‘DO NOT USE’” on the box.

A spokesperson for the Manitoba government said about 64,000 doses were distributed from this lot.

It’s unclear how many were actually administered. Global News has emailed the province for clarification but has not heard back yet.

In contrast, 525,000 doses were shipped to Manitoba that were not from this lot.

“Although no neurological or serious adverse events associated with this lot have been reported in Manitoba, out of an abundance of caution, providers are being asked to set aside doses from that lot and not use it until more information is available,” a provincial spokesperson said.

“Manitoba is working with federal and provincial partners through the national procurement process to determine how these doses may be replaced, if necessary. There is low risk to the public and no further action is needed from any Manitoban who has already received a flu vaccine.”